Authors
Loading...
Preclinical research demonstrates therapeutic benefits of enhanced reverse cholesterol transport in atherosclerosis models, highlighting high-density lipoproteins as drug targets.
Christopher J. Fielding (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: